Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 9

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 9
---
 the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test, which is a laboratory developed test, to be re-introduced to the U.S. market starting in the second quarter of 2025 after we complete a
number of steps related to certifications, state licensure, payor coverages, reimbursement codes and financing.

Company Information

In March 2025, we moved our headquarters to Houston, Texas, in proximity to world-class cancer institutions and researchers. Our principal executive offices
are located at 2710 Reed Road, Suite 160, Houston, Texas 77051, and our telephone number is (737) 255-7194. We maintain a website at www.plustherapeutics.com. We make available free of charge through our
website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to these
reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon as reasonably practicable after we electronically file such material with, or furnish such
material to, the SEC. These reports and other information are also available, free of charge, at www.sec.gov. Information contained on, or that can be accessed through, the websites referenced in this prospectus are not a part of, or incorporated by
reference into, this prospectus.

1

The Offering

| Issuer | Plus Therapeutics, Inc. |

| Common stock offered by the Selling Stockholders | Up to 1,565,044,860 shares of common stock, including (i) 3,077,270 shares of common stock, (ii) 19,650,000 shares of common stock issuable upon exercise of Pre-Funded Warrants,                                                          
 (iii) 280,421,380 shares of common stock that could become issuable upon exercise of Series A Common Stock Warrants, (iv) 1,261,896,210 shares of common stock that could become issuable upon exercise of Series B Common Stock Warrants, 
 which we issued in a private placement transaction (the “March PIPE Financing”) pursuant to the Purchase Agreement, among us and the Purchasers.                                                                                           |

| Use of proceeds | We are not selling any securities under this prospectus and will not receive any proceeds from the sale of the shares of common stock by the selling stockholders covered by this prospectus. We